share_log

Oppenheimer Maintains Outperform on Jasper Therapeutics, Maintains $80 Price Target

Moomoo 24/7 ·  Mar 7 08:02

Oppenheimer analyst Jay Olson maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and maintains $80 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment